Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities
about
Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus.Development of live attenuated influenza vaccines against pandemic influenza strains.Health and economic benefits of early vaccination and nonpharmaceutical interventions for a human influenza A (H7N9) pandemic: a modeling studyPhase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009.Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005-2011Influenza vaccination in India: position paper of Indian Academy of Pediatrics, 2013.Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design.Interim estimates of 2013-14 seasonal influenza vaccine effectiveness - United States, February 2014.Protective effects of influenza A (H1N1) pandemic 2009 vaccination against the onset of influenza-like illness and asthma exacerbation in Japanese children.Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children.Effectiveness of pandemic and seasonal influenza vaccines in preventing laboratory-confirmed influenza in adults: a clinical cohort study during epidemic seasons 2009-2010 and 2010-2011 in Finland.Antiviral treatment among older adults hospitalized with influenza, 2006-2012Deaths averted by influenza vaccination in the U.S. during the seasons 2005/06 through 2013/14.Safety, immunogenicity and infectivity of new live attenuated influenza vaccines.Substantial Influenza Vaccine Effectiveness in Households With Children During the 2013-2014 Influenza Season, When 2009 Pandemic Influenza A(H1N1) Virus PredominatedInfluenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States.Evaluating the case-positive, control test-negative study design for influenza vaccine effectiveness for the frailty biasEffect of vaccines and antivirals during the major 2009 A(H1N1) pandemic wave in Norway--and the influence of vaccination timing.Decreased serologic response in vaccinated military recruits during 2011 correspond to genetic drift in concurrent circulating pandemic A/H1N1 viruses.Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom.Effectiveness of monovalent 2009 pandemic influenza A virus subtype H1N1 and 2010-2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010-2011 influenza season.The first, second and third wave of pandemic influenza A (H1N1)pdm09 in North Denmark Region 2009-2011: a population-based study of hospitalizations.Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates.Factors associated with influenza vaccine receipt in community dwelling adults and their children.Geographical heterogeneity and influenza infection within households.Seasonal incidence of medically attended respiratory syncytial virus infection in a community cohort of adults ≥50 years oldImpact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons.Estimating the influenza vaccine effectiveness against medically attended influenza in clinical settings: a hospital-based case-control study with a rapid diagnostic test in JapanPotential of the test-negative design for measuring influenza vaccine effectiveness: a systematic reviewInfluenza-related hospitalization and ED visits in children less than 5 years: 2000-2011.Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination.Influenza vaccine effectiveness against hospitalisation with confirmed influenza in the 2010-11 seasons: a test-negative observational studyInfluenza vaccine prevents medically attended influenza-associated acute respiratory illness in adults aged ≥50 yearsClinical effectiveness of split-virion versus subunit trivalent influenza vaccines in older adultsInfluenza vaccine effectiveness in households with children during the 2012-2013 season: assessments of prior vaccination and serologic susceptibility.H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance.Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine.Hospitalizations and outpatient visits for rhinovirus-associated acute respiratory illness in adultsEffectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains.Influenza vaccine effectiveness in the community and the household
P2860
Q30205252-33AC7F82-A743-4FD0-94FF-C2A90FE65F2EQ30209998-33C9EACE-3815-403C-A18B-0B9CC72E6F22Q30210097-198217C4-6AE7-4CB1-A605-A8FAFBC327DAQ30224646-0C3F0C00-C8F5-4CD5-AB15-49DF98EFE98CQ30351995-449D83C6-3CA3-4566-9D3E-B69ABB36734FQ30354181-BC66D151-03CA-47D8-860F-E2CE499DE244Q30358954-0EDC5100-A1D6-469E-9F5E-2AF4AA57A46FQ30359268-D25962E0-CB7E-4EAA-9607-E6E17AB6C31EQ30361429-41737FF9-6637-4E82-B524-D81E7D257390Q30366806-B3C2E5B8-258D-4C48-9F8B-F04A11794127Q30367263-59309BE4-F780-4EEB-BC39-E5D6EFA51FCEQ30373020-F2B64C1D-F69E-413C-A636-05063AF23AE2Q30373099-2CF168EF-B88C-4C8D-B847-8BAA644E9C6FQ30378132-8A386BDF-966A-4983-974E-9DD35BBB0F79Q30381731-8227F5F5-F9B7-4B26-929B-EED68A71667AQ30383312-926AC456-8621-479D-B1FA-EA6659671F89Q30385102-76B62BFD-C561-4C4D-AD9B-BE2D74F962E0Q30411896-4D840A37-CB54-403A-ABCD-7CE9ECD78890Q30415565-A002314E-EE03-46F7-8BDD-6F7F5BFCEE75Q30417900-489783B2-E606-4AF1-8E4C-500A3CD535B6Q30426206-F2725233-68A6-4D2C-AC17-57CA479CA1B6Q30427049-17145B8E-E580-496A-87FB-3601BB65032BQ33554684-E3A0619F-8837-4C52-A3FC-4BB57E959041Q33855410-8CB8B485-105F-4839-AEF5-3C4C0D84AC6FQ33891510-A587928F-CC7E-4109-93AA-2C66285F239CQ33905511-4FBB132C-E816-49E6-894A-77D8E4BD2FA2Q34393525-0958A71B-233E-45B5-8A99-DE739EFA8F9FQ34550913-5F7F87EC-984B-40B6-9FAF-852E262F2E9EQ34778408-4D9153F6-4A96-4347-8773-3959CFADFB9BQ34785408-897D96CA-AE56-4D87-936F-E0879A1D665FQ34805068-FEBCCED5-93D3-4C76-828E-C6739E33A869Q34850986-E12311D6-5F53-4E37-8ACA-5907507B348AQ35608431-03FD84E6-F9CF-4862-AB45-287319C5947BQ35661715-66FF8CC4-E42B-4FFC-8122-F0C05F0065E4Q35715694-42BD5AFA-69F1-463B-8D42-29F3D2EC7BECQ36255850-EEC00E4D-20E7-4EB4-988B-D299C3DEA94EQ36518793-32B5CD0B-D00B-479B-BAC5-09FF830978B8Q36553919-6E1293FE-C957-4500-94BE-89C3AD2935E1Q36854011-84555504-DA80-4C53-9CA9-FBA0E9EB7135Q36956943-7C87F25A-193C-4224-81EC-64507D439842
P2860
Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Effectiveness of non-adjuvante ...... s visits in 4 U.S. communities
@ast
Effectiveness of non-adjuvante ...... s visits in 4 U.S. communities
@en
Effectiveness of non-adjuvante ...... s visits in 4 U.S. communities
@nl
type
label
Effectiveness of non-adjuvante ...... s visits in 4 U.S. communities
@ast
Effectiveness of non-adjuvante ...... s visits in 4 U.S. communities
@en
Effectiveness of non-adjuvante ...... s visits in 4 U.S. communities
@nl
prefLabel
Effectiveness of non-adjuvante ...... s visits in 4 U.S. communities
@ast
Effectiveness of non-adjuvante ...... s visits in 4 U.S. communities
@en
Effectiveness of non-adjuvante ...... s visits in 4 U.S. communities
@nl
P2093
P2860
P50
P1433
P1476
Effectiveness of non-adjuvante ...... s visits in 4 U.S. communities
@en
P2093
Caroline Breese Hall
Gerry Lofthus
H Keipp Talbot
Jennifer K Meece
John J Treanor
Joshua G Petrie
LaShondra Berman
Laura A Coleman
Marie R Griffin
P2860
P304
P356
10.1371/JOURNAL.PONE.0023085
P407
P577
2011-01-01T00:00:00Z